NASDAQ:AEZS - AEterna Zentaris Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.85 -0.05 (-1.72 %)
(As of 12/18/2018 02:33 PM ET)
Previous Close$2.90
Today's Range$2.85 - $2.92
52-Week Range$1.12 - $3.92
Volume12,090 shs
Average Volume503,485 shs
Market Capitalization$46.85 million
P/E Ratio-2.12
Dividend YieldN/A
Beta0.91
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. It also has a collaboration agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for the development, manufacture, and commercialization of Zoptrex, which has completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer in the People's Republic of China. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AEZS
Previous Symbol
CUSIPN/A
Phone843-900-3223

Debt

Debt-to-Equity RatioN/A
Current Ratio3.64
Quick Ratio3.34

Price-To-Earnings

Trailing P/E Ratio-2.12
Forward P/E Ratio6.48
P/E GrowthN/A

Sales & Book Value

Annual Sales$920,000.00
Price / Sales50.93
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.17) per share
Price / Book-16.76

Profitability

EPS (Most Recent Fiscal Year)($1.35)
Net Income$-16,790,000.00
Net Margins34.40%
Return on Equity83.33%
Return on Assets18.03%

Miscellaneous

Employees34
Outstanding Shares16,440,000
Market Cap$46.85 million
OptionableOptionable

AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (NASDAQ:AEZS) issued its quarterly earnings data on Tuesday, November, 6th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.10. The biopharmaceutical company earned $0.66 million during the quarter. AEterna Zentaris had a return on equity of 83.33% and a net margin of 34.40%. View AEterna Zentaris' Earnings History.

When is AEterna Zentaris' next earnings date?

AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for AEterna Zentaris.

What price target have analysts set for AEZS?

2 equities research analysts have issued 1-year price targets for AEterna Zentaris' stock. Their predictions range from $3.00 to $4.00. On average, they anticipate AEterna Zentaris' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 22.8% from the stock's current price. View Analyst Price Targets for AEterna Zentaris.

What is the consensus analysts' recommendation for AEterna Zentaris?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AEterna Zentaris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AEterna Zentaris.

What are Wall Street analysts saying about AEterna Zentaris stock?

Here are some recent quotes from research analysts about AEterna Zentaris stock:
  • 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (11/16/2018)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of AEZS and adjust our 12-month price target to $3.00 per share. We derived our price target based on the average of two valuation methods: (1) price-sales multiple using 8x 2025 sales estimate discounted at 18%; and (2) price-earnings multiple using 25x 2025 earnings estimate also discounted at 18%." (11/14/2018)

Has AEterna Zentaris been receiving favorable news coverage?

News stories about AEZS stock have trended somewhat positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AEterna Zentaris earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the company's share price in the near term.

Who are some of AEterna Zentaris' key competitors?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:
  • Mr. Michael V. Ward, Pres & CEO (Age 61)
  • Ms. Leslie Auld, Sr. VP & CFO
  • Mr. Brian Garrison, Sr. VP of Global Corp. Operations & Corp. Devel.
  • Mr. Paul Burroughs, Director of Communications
  • Dr. Nicola Ammer, Chief Medical Officer & VP of Clinical Devel.

Who are AEterna Zentaris' major shareholders?

AEterna Zentaris' stock is owned by a number of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.31%).

Which institutional investors are buying AEterna Zentaris stock?

AEZS stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC.

How do I buy shares of AEterna Zentaris?

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $2.85.

How big of a company is AEterna Zentaris?

AEterna Zentaris has a market capitalization of $46.85 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-16,790,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. AEterna Zentaris employs 34 workers across the globe.

What is AEterna Zentaris' official website?

The official website for AEterna Zentaris is http://www.aezsinc.com.

How can I contact AEterna Zentaris?

AEterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 843-900-3223 or via email at [email protected]


MarketBeat Community Rating for AEterna Zentaris (NASDAQ AEZS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  550
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Featured Article: Municipal Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel